Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Wednesday, setting a price target of $100, which is approximately 22.12% above the present share price of $81.89.
Harrison expects Denali Therapeutics to post earnings per share (EPS) of -$0.54 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Denali Therapeutics, with an average price target of $78.
The analysts price targets range from a high of $100 to a low of $64.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $9.39 million and a net profit of -$60.12 million. The company's market cap is $9.6 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.2% and a 62.63% success rate.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.